GLP-1 drugs for eating disorders: Nov. 17 review finds mixed evidence and flags risks
Some small studies suggest a benefit for binge-eating symptoms, but a pilot trial found no clear advantage over placebo. The review also raises concerns about restrictive eating.
In this article & details
A review published Nov. 17 in Current Psychiatry Reports found mixed evidence on whether GLP-1 receptor agonists improve binge-eating symptoms and warned that the same effects on appetite could make restrictive eating harder to detect. The authors reviewed existing studies; they did not report results from a new clinical trial.
Observational findings and a small trial point in different directions
The authors found that some studies reported larger reductions in binge-eating symptoms with GLP-1 drugs than with comparison medicines. One was a retrospective study of semaglutide, meaning the researchers looked at treatment that had already taken place rather than assigning participants to groups. A small randomized pilot study of liraglutide did not find a statistically significant advantage over placebo for the binge-eating outcome. The review pointed to the need for stronger evidence before drawing conclusions about benefit.
That distinction matters because a change in appetite or body weight is not the same as sustained improvement in an eating disorder. The review discusses possible effects on food reward and compulsive eating, but says the evidence base remains sparse.
Appetite suppression may obscure restrictive symptoms
The authors raised a different concern for people vulnerable to anorexia nervosa or atypical anorexia nervosa: a medicine that suppresses appetite could facilitate or conceal restrictive eating. They noted that people with eating disorders were excluded from clinical development trials, leaving limited evidence about how often these harms occur. The review describes a possible risk, not a measured rate of new or recurrent eating disorders.
The review does not change Canadian product indications
Health Canada identifies GLP-1 medicines as prescription drugs with authorized uses that include type 2 diabetes or obesity, depending on the product. The Canadian Wegovy product record and monograph do not list treatment of an eating disorder as an indication. The review calls for better studies of how these drugs affect different eating disorders, including the safety and durability of any benefit.
References
- Miracle and/or Minefield? GLP-1 RA Drugs and Eating Disorders — Current Psychiatry Reports, Open-access review, Nov. 17, 2026
- Thinking about buying GLP-1 drugs like Ozempic or Mounjaro? — Health Canada, Canadian prescription and authorization context
- Wegovy: Canadian product information and monograph — Health Canada Drug Product Database, Product indications